WHO Advises Doctors Not to Use Gilead’s Remdesivir for Covid (4)

Nov. 20, 2020, 3:47 PM

The World Health Organization recommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.

“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal.

The recommendation is a blow to Gilead’s drug, which was one of the first thought to offer a meaningful benefit to coronavirus patients after a study showed it reduced their recovery time. The antiviral has been used widely to treat Covid...

To read the full article log in.

Learn more about a Bloomberg Law subscription.